Lonza Netherlands, former PharmaCell Revenue and Competitors

Claim your profile

Maastricht, Netherlands

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Lonza Netherlands, former PharmaCell's estimated annual revenue is currently $55.5M per year.(i)
  • Lonza Netherlands, former PharmaCell's estimated revenue per employee is $201,000

Employee Data

  • Lonza Netherlands, former PharmaCell has 276 Employees.(i)
  • Lonza Netherlands, former PharmaCell grew their employee count by 11% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.7M630%N/AN/A
#2
$258.3M1285-2%N/AN/A
#3
$2.4M129%N/AN/A
#4
$258.3M1285-2%N/AN/A
#5
$16.7M83-31%N/AN/A
#6
$75.6M376132%N/AN/A
#7
$55.5M27611%N/AN/A
#8
$34.4M1719%N/AN/A
#9
$27.7M1381%N/AN/A

Lonza Netherlands is a Contract Manufacturing Organization (CMO) in the area of cell therapy and regenerative medicine (tissue culturing). The company works with European and US-based biotechnology companies on pre-clinical, clinical to commercial development projects and offers GMP and regulatory consultancy, cell culturing process development, fill and finish, Quality Control (QC)-testing and Good Manufacturing Practices (GMP) production services, as well as storage and distribution of clinical trial materials. PharmaCell is located in the center of Europe and operates two state-of-the-art cGMP-licensed facilities for human cell & tissue culturing in Maastricht and Geleen (Netherlands), conveniently located at approximately one hour driving distance from Brussels, Antwerp, Cologne and Dusseldorf.

keywords:N/A

N/A

Total Funding

276

Number of Employees

$55.5M

Revenue (est)

11%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Lonza Netherlands, former PharmaCell News

2019-06-19 - Lonza building capacity for Gamida’s bone marrow transplant

Lonza will construct suites at its site in The Netherlands dedicated to producing ... did not divulge financial terms of the deal but old Bioprocess Insider his ... gene therapy network through the acquisition of PharmaCell in 2017.

2017-06-09 - Lonza plugs EU cell and gene therapy gap through ...

The acquisition of Dutch commercial cell and gene therapy maker PharmaCell places Lonza as the leading CDMO in the space, the firm says.

2017-06-01 - Lonza buys Dutch cell and gene therapy CMO

Visp, Switzerland-based Lonza has acquired Dutch gene and cell contract therapy manufacturer PharmaCell because of its expertise with ...